Pretreatment with different loading doses of clopidogrel influences P-selectin levels in patients undergoing percutaneous coronary intervention: Results from the ARMYDA-2 (antiplatelet therapy for reduction of myocardial damage during angioplasty) SELECT substudy

Journal of Cardiovascular Medicine

Volumn 12, Issue 3, 2011, Pages 151-156

  Patti, Giuseppe ^a   Chello, Massimo ^a   Pasceri, Vincenzo ^b   Colonna, Diego ^c   Colonna, Giuseppe ^d   Pepe, Leonardo Lassandro ^a   Montinaro, Antonio ^d   Covino, Elvio ^a   Di Sciascio, Germano ^a  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b SAN FILIPPO NERI HOSPITAL   (Italy)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

^d VITO FAZZI HOSPITAL   (Italy)

Author keywords

clopidogrel; myocardial injury; P selectin; percutaneous coronary intervention

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PADGEM PROTEIN; TROPONIN I;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG DOSE COMPARISON; FEMALE; HEART MUSCLE INJURY; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL;

AGED; ANALYSIS OF VARIANCE; ANGIOPLASTY, BALLOON, CORONARY; BIOLOGICAL MARKERS; CHI-SQUARE DISTRIBUTION; CORONARY ARTERY DISEASE; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEART DISEASES; HUMANS; ITALY; MALE; MIDDLE AGED; P-SELECTIN; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; TICLOPIDINE; TIME FACTORS; TREATMENT OUTCOME; TROPONIN I;

EID: 79953654784     PISSN: 15582027     EISSN: None     Source Type: Journal    
DOI: 10.2459/JCM.0b013e3283410311     Document Type: Article

References (20)

1. Patti G, Colonna G, Pasceri V, Lassandro Pepe L, Montinaro A, Di Sciascio G. A Randomized Trial of High Loading Dose of Clopidogrel for Reduction of Peri-procedural Myocardial Infarction in Patients Undergoing Coronary Intervention. Results From the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) Study. Circulation 2005; 111:2099-2106.
2. Muller I, Seyfarth M, Rudiger S, Wolf B, Pogatsa-Murray G, Schömig A, Gawaz M. Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement. Heart 2001; 85:92-93. (Pubitemid 32973418)
3. Moussa I, Oetgen M, Roubin G, Colombo A, Wang X, Iyer S, et al. Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation. Circulation 1999; 99:2364-2366. (Pubitemid 29218228)
4. Inoue T, Hoshi K, Yaguchi I, Iwasaki Y, Takayanagi K, Morooka S. Serum levels of circulating adhesion molecules after coronary angioplasty. Cardiology 1999; 91:236-242. (Pubitemid 29502086)
5. Angiolillo D, Fernàndez-Ortiz A, Bernardo E, Ramírez C, Sabaté M, Bañuelos C, et al. High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability. Eur Heart J 2004; 25:1903-1910. (Pubitemid 39452607)
6. Andrè P. P-selectin in haemostasis. Br J Haematol 2004; 126:298-306. (Pubitemid 39005709)
7. Seyfarth HJ, Koksch M, Roethig G, Rother T, Neugebauer A, Klein N, Pfeiffer D. Effect of 300- and 450-mg clopidogrel loading doses on membrane and soluble P-selectin in patients undergoing coronary stent implantation. Am Heart J 2002; 143:118-123. (Pubitemid 34056384)
8. Romo GM, Dong JF, Schade AJ, Gardiner EE, Kansas GS, Li CQ, et al. The glycoprotein Ib-IX-V complex is a platelet counterreceptor for P-selectin. J Exp Med 1999; 190:803-814.
9. McEver RP, Cummings RD. Perspectives series: cell adhesion in vascular biology. Role of PSGL-1 binding to selectins in leukocyte recruitment. J Clin Invest 1997; 100:485-491.
10. Celi A, Pellegrini G, Lorenzet R, De Blasi A, Ready N, Furie BC, Furie B. P-selectin induces the expression of tissue factor on monocytes. Proc Natl Acad Sci U S A 1994; 91:8767-8771.
11. Dunlop LC, Skinner MP, Bendall LJ, Favaloro EJ, Castaldi PA, Gorman JJ, et al. Characterization of GMP-140 (P-selectin) as a circulating plasma protein. J Exp Med 1992; 175:1147-1150.
12. Mulvihill NT, Foley JB, Walsh MA, Crean PA. Relationship between intracoronary and peripheral expression of soluble cell adhesion molecules. Int J Cardiol 2001; 77:223-229. (Pubitemid 32155908)
13. Andre P, Hartwell D, Hrachovinova I, Saffaripour S, Wagner DD. Procoagulant state resulting from high levels of soluble P-selectin in blood. Proc Natl Acad Sci U S A 2000; 97:13835-13840.
14. Inoue T, Sohma R, Miyazaki T, Iwasaki Y, Yaguchi I, Morooka S. Comparison of activation process of platelets and neutrophils after coronary stent implantation versus balloon angioplasty for stable angina pectoris. Am J Cardiol 2000; 86:1057-1062.
15. Hochholzer W, Trenk D, Frundi D, Blanke P, Fischer B, Andris K, et al. Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention. Circulation 2005; 111:2560-2564.
16. Helft G, Osende JI, Worthley SG, Zaman AG, Rodriguez OJ, Lev EI, et al. Acute antithrombotic effect of a front-loaded regimen of clopidogrel in patients with atherosclerosis on aspirin. Arterioscler Thromb Vasc Biol 2000; 20:2316-2321.
17. Patti G, Nusca A, Mangiacapra F, Gatto L, D'Ambrosio A, Di Sciascio G. Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention. Results of the ARMYDA-PRO (Antiplatelet Therapy for Reduction of MYocardial Damage During Angioplasty: Platelet Reactivity Predicts Outcome) Study. J Am Coll Cardiol 2008; 52:1128-1133.
18. The EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty- controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Evaluation of platelet IIb/IIIa inhibitor for stenting. Lancet 1998; 352:87-92.
19. Mayadas TN, Johnson RC, Rayburn H, Hynes RO, Wagner DD. Leukocyte rolling and extravasation are severely compromised in P selectin-deficient mice. Cell 1993; 74:541-554. (Pubitemid 23244619)
20. Patti G, Chello M, Pasceri V, Colonna D, Nusca A, Miglionico M, et al. Protection from procedural myocardial injury by atorvastatin is associated with lower levels of adhesion molecules after percutaneous coronary intervention: results from the ARMYDA-CAMs (Atorvastatin for Reduction of MYocardial Damage during Angioplasty-Cell Adhesion Molecules) substudy. J Am Coll Cardiol 2006; 48:1560-1566. (Pubitemid 44528186)